Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.

@article{Namba2004GefitinibIP,
  title={Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.},
  author={Yoshinobu Namba and Takashi Kijima and Soichiro Yokota and Manabu Niinaka and Satolo Kawamura and Takeo Iwasaki and Yoshito Takeda and Hiromi Kimura and Tatsuya Okada and Toshihiko Yamaguchi and Masaru Nakagawa and Yoshimoto Okumura and Hajime Maeda and Masami Ito},
  journal={Clinical lung cancer},
  year={2004},
  volume={6 2},
  pages={123-8}
}
The clinical efficacy of gefitinib, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), on brain metastases (BMs) from non-small-cell lung cancer (NSCLC) was evaluated. Fifteen patients with recurrent NSCLC with metastasis to the brain were treated with gefitinib. The objective tumor response rate (60%; 9 of 15 patients) for BM was the same as for primary tumors. The median time to response of BM was 26 days. In 8 of 9 patients who exhibited partial response in the thoracic… CONTINUE READING
61 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 61 extracted citations

Similar Papers

Loading similar papers…